Quick Answer
PAVmed Inc. reported Operating Income Loss of -$21.81 million for the year ending 2025.
- PAVmed Inc. showed an increase of +51.0% in Operating Income Loss from 2024 to 2025.
- This data is from PAVmed Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$696.9 thousand | Q2 2016: -$1.31 million | Q3 2016: -$1.93 million | Q1 2017: -$2.16 million | Q2 2017: -$2.02 million | Q3 2017: -$1.97 million | Q1 2018: -$1.94 million | Q2 2018: -$2.74 million | Q3 2018: -$2.57 million | Q1 2019: -$3.14 million | Q2 2019: -$3.32 million | Q3 2019: -$3.24 million | Q1 2020: -$5.25 million | Q2 2020: -$5.01 million | Q3 2020: -$5.53 million | Q1 2021: -$8.08 million | Q2 2021: -$12.97 million | Q3 2021: -$13.67 million | Q1 2022: -$19.64 million | Q2 2022: -$23.48 million | Q3 2022: -$23.37 million | Q1 2023: -$20.40 million | Q2 2023: -$16.48 million | Q3 2023: -$15.53 million | Q1 2024: -$14.04 million | Q2 2024: -$13.68 million | Q3 2024: -$11.58 million | Q1 2025: -$5.45 million | Q2 2025: -$4.72 million | Q3 2025: -$4.84 million.
- Over the full 10 years of available data (2016 to 2025), PAVmed Inc.'s Operating Income Loss has declined by 285.9%.
- Historical annual values: Fiscal year 2025: -$21.81 million | Fiscal year 2024: -$44.49 million | Fiscal year 2023: -$68.80 million | Fiscal year 2022: -$91.09 million | Fiscal year 2021: -$54.39 million | Fiscal year 2020: -$23.35 million | Fiscal year 2019: -$14.30 million | Fiscal year 2018: -$10.56 million | Fiscal year 2017: -$8.03 million | Fiscal year 2016: -$5.65 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: